Use of Δ5-androstene-3β-ol-7,17-dione in the treatment of lupus erythematosus
US6924274B2 · kind B2 · utility
58Cited by
10References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 2003 |
| Grant date | Aug 2, 2005 |
| Priority date | — |
| Expiry date | Jun 18, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Lupus erythematosus can be treated by administering therapeutic amounts of Δ5-androstene-3β-ol-7,17-dione and metabolizable precursors thereof, such as Δ5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to Δ5-androstene-3β-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.